TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from HUTCHMED (China) ( (HK:0013) ) is now available.
HUTCHMED announced that it will present new and updated clinical data from several studies at the ESMO Congress 2025 in Berlin. The presentations will include results from the FRUSICA-2 study on the combination of fruquintinib and sintilimab for renal cell carcinoma, as well as analyses of studies involving fruquintinib in endometrial and colorectal cancer, and savolitinib in non-small cell lung cancer. These data presentations underscore HUTCHMED’s ongoing efforts to advance its oncology pipeline and strengthen its position in the cancer treatment market.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company collaborates with global pharmaceutical firms like Eli Lilly and AstraZeneca to co-develop and commercialize its products, such as fruquintinib and savolitinib, in various markets.
Average Trading Volume: 10,785,382
Technical Sentiment Signal: Hold
Current Market Cap: HK$21.45B
See more insights into 0013 stock on TipRanks’ Stock Analysis page.